Effects of atropine, trimedoxime and methylprednisolone on the development of organophosphate-induced delayed polyneuropathy in the hen.
In this study we have examined the effects of atropine, trimedoxime (TMB-4) and methylprednisolone (MP) on the development of organophosphate-induced delayed polyneuropathy (OPIDP) in the hen. The birds were treated with standard neuropathic dose of diisopropylfluorophosphate (DFP) (1.1 mg/kg, sc), which produced OPIDP that could be graded as 5 on the 8-point scale, and the development of OPIDP was observed for the next 22 days. The results obtained have shown that atropine (20 mg/kg, ip), TMB-4 (15 mg/kg, im) and MP (2 or 10 mg/kg, ip) either alone or in different combinations are able to improve the condition of the birds. The most potent effect was obtained with atropine, TMB-4 (given 20 min before DFP) and MP (2 mg/kg, sc, given 20 min before and at 48 hour intrevals after poisoning) since the signs of OPIDP could hardly be seen (grade 1 at the 8-point scale). When TMB-4 and MP were given 15 or 40 min after DFP the protective/therapeutic effects of these drugs appeared to be diminished since walking disorders were more serious and graded as 2 or 4, respectively. The possible mechanisms of the action of the drugs in respect to OPIDP are discussed. In conclusion, the results of this study have shown that it is possible to prevent the development of DFP-induced OPIDP in the hen by treatment with atropine, trimedoxime and methylprednisolone when they were given before or soon after DFP.
Jokanović
M
M
Department of Pharmacology, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe.
Stepanović Petrović
R M
RM
Maksimović
M
M
Jovanovic
D
D
Kosanović
M
M
Piperski
V
V
D000818:Animals; D001259:Ataxia / Q000517:prevention & control; D001285:Atropine / Q000627:therapeutic use*; D002645:Chickens; D004359:Drug Therapy, Combination; D005260:Female; D007531:Isoflurophate / Q000633:toxicity; D008775:Methylprednisolone / Q000627:therapeutic use*; D009068:Movement / Q000187:drug effects / Q000502:physiology; D010243:Paralysis / Q000517:prevention & control; D011115:Polyneuropathies / Q000139:chemically induced / Q000473:pathology / Q000503:physiopathology / Q000517:prevention & control*; D014289:Trimedoxime / Q000627:therapeutic use*
D007531:Isoflurophate; D014289:Trimedoxime; D001285:Atropine; D008775:Methylprednisolone